Development and prognosis of hepatocellular carcinoma in patients with diabetes

The incidence of diabetes mellitus and hepatocellular carcinoma (HCC) has been increasing worldwide during the last few decades, in the context of an increasing prevalence of obesity and non-alcoholic fatty liver disease (NAFLD). Epidemiologic studies have revealed that patients with diabetes have a...

Full description

Bibliographic Details
Main Authors: Takuma Nakatsuka, Ryosuke Tateishi
Format: Article
Language:English
Published: Korean Association for the Study of the Liver 2023-01-01
Series:Clinical and Molecular Hepatology
Subjects:
Online Access:http://e-cmh.org/upload/pdf/cmh-2022-0095.pdf
_version_ 1797952254480744448
author Takuma Nakatsuka
Ryosuke Tateishi
author_facet Takuma Nakatsuka
Ryosuke Tateishi
author_sort Takuma Nakatsuka
collection DOAJ
description The incidence of diabetes mellitus and hepatocellular carcinoma (HCC) has been increasing worldwide during the last few decades, in the context of an increasing prevalence of obesity and non-alcoholic fatty liver disease (NAFLD). Epidemiologic studies have revealed that patients with diabetes have a 2- to 3-fold increased risk of developing HCC, independent of the severity and cause of the underlying liver disease. A bidirectional relationship exists between diabetes and liver disease: advanced liver disease promotes the onset of diabetes, and HCC is an important cause of death in patients with diabetes; conversely, diabetes is a risk factor for liver fibrosis progression and HCC development, and may worsen the long-term prognosis of patients with HCC. The existence of close interconnections among diabetes, obesity, and NAFLD causes insulin resistance-related hyperinsulinemia, increased oxidative stress, and chronic inflammation, which are assumed to be the underlying causes of hepatocarcinogenesis in patients with diabetes. No appropriate surveillance methods for HCC development in patients with diabetes have been established, and liver diseases, including HCC, are often overlooked as complications of diabetes. Although some antidiabetic drugs are expected to prevent HCC development, further research on the optimal use of antidiabetic drugs aimed at hepatoprotection is warranted. Given the increasing medical and socioeconomic impact of diabetes on HCC development, diabetologists and hepatologists need to work together to develop strategies to address this emerging health issue. This article reviews the current knowledge on the impact of diabetes on the development and progression of HCC.
first_indexed 2024-04-10T22:44:29Z
format Article
id doaj.art-fd45c5086e2149bf83b86e09e5c7d96a
institution Directory Open Access Journal
issn 2287-2728
2287-285X
language English
last_indexed 2024-04-10T22:44:29Z
publishDate 2023-01-01
publisher Korean Association for the Study of the Liver
record_format Article
series Clinical and Molecular Hepatology
spelling doaj.art-fd45c5086e2149bf83b86e09e5c7d96a2023-01-16T00:56:06ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2023-01-01291516410.3350/cmh.2022.00951696Development and prognosis of hepatocellular carcinoma in patients with diabetesTakuma Nakatsuka0Ryosuke Tateishi Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, JapanThe incidence of diabetes mellitus and hepatocellular carcinoma (HCC) has been increasing worldwide during the last few decades, in the context of an increasing prevalence of obesity and non-alcoholic fatty liver disease (NAFLD). Epidemiologic studies have revealed that patients with diabetes have a 2- to 3-fold increased risk of developing HCC, independent of the severity and cause of the underlying liver disease. A bidirectional relationship exists between diabetes and liver disease: advanced liver disease promotes the onset of diabetes, and HCC is an important cause of death in patients with diabetes; conversely, diabetes is a risk factor for liver fibrosis progression and HCC development, and may worsen the long-term prognosis of patients with HCC. The existence of close interconnections among diabetes, obesity, and NAFLD causes insulin resistance-related hyperinsulinemia, increased oxidative stress, and chronic inflammation, which are assumed to be the underlying causes of hepatocarcinogenesis in patients with diabetes. No appropriate surveillance methods for HCC development in patients with diabetes have been established, and liver diseases, including HCC, are often overlooked as complications of diabetes. Although some antidiabetic drugs are expected to prevent HCC development, further research on the optimal use of antidiabetic drugs aimed at hepatoprotection is warranted. Given the increasing medical and socioeconomic impact of diabetes on HCC development, diabetologists and hepatologists need to work together to develop strategies to address this emerging health issue. This article reviews the current knowledge on the impact of diabetes on the development and progression of HCC.http://e-cmh.org/upload/pdf/cmh-2022-0095.pdfhepatocellular carcinomadiabetes mellitusinsulin resistancehyperinsulinemianon-alcoholic fatty liver disease
spellingShingle Takuma Nakatsuka
Ryosuke Tateishi
Development and prognosis of hepatocellular carcinoma in patients with diabetes
Clinical and Molecular Hepatology
hepatocellular carcinoma
diabetes mellitus
insulin resistance
hyperinsulinemia
non-alcoholic fatty liver disease
title Development and prognosis of hepatocellular carcinoma in patients with diabetes
title_full Development and prognosis of hepatocellular carcinoma in patients with diabetes
title_fullStr Development and prognosis of hepatocellular carcinoma in patients with diabetes
title_full_unstemmed Development and prognosis of hepatocellular carcinoma in patients with diabetes
title_short Development and prognosis of hepatocellular carcinoma in patients with diabetes
title_sort development and prognosis of hepatocellular carcinoma in patients with diabetes
topic hepatocellular carcinoma
diabetes mellitus
insulin resistance
hyperinsulinemia
non-alcoholic fatty liver disease
url http://e-cmh.org/upload/pdf/cmh-2022-0095.pdf
work_keys_str_mv AT takumanakatsuka developmentandprognosisofhepatocellularcarcinomainpatientswithdiabetes
AT ryosuketateishi developmentandprognosisofhepatocellularcarcinomainpatientswithdiabetes